Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04311411 · ClinicalTrials.gov registry record · Phase 1

A Study of Tirzepatide in Overweight and Very Overweight Participants

A Phase 1 study of Obesity and Overweight, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
114
Enrollment target
3
Study locations

NCT04311411 is a Phase 1 study of Obesity and Overweight that has completed, run by Eli Lilly and Company. The registered enrollment target is 114 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04311411, a Phase 1 study of Obesity and Overweight, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
114 participants
Enrollment target
3
Study locations

Study Summary

The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be studied. The study will last up to about four months and will include up to 14 visits to the study center.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Tirzepatide
  • DRUG Liraglutide

Study Locations (3)

Indiana

  • Indiana University School of Medicine - Indianapolis

Louisiana

  • Pennington Biomedical Research Center - Baton Rouge

Maryland

  • Johns Hopkins University School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2020-08-24
Est. Completion 2022-12-16
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT04311411

The ClinicalTrials.gov registry entry for NCT04311411 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (86% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04311411 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Indiana, Louisiana, Maryland.

Frequently Asked Questions

What is clinical trial NCT04311411 about?

NCT04311411 is a clinical study titled "A Study of Tirzepatide in Overweight and Very Overweight Participants". The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be stu...

What is the current status of trial NCT04311411?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2020-08-24. Estimated completion is 2022-12-16.

What conditions does trial NCT04311411 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT04311411?

The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), Liraglutide (DRUG).

Who is sponsoring clinical trial NCT04311411?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04311411 being conducted?

This trial has 3 study locations across Indiana, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.